Robinson B F, Bayley S, Dobbs R J
Hypertension. 1983 Jul-Aug;5(4 Pt 2):II122-4. doi: 10.1161/01.hyp.5.4_pt_2.ii122.
Verapamil and nifedipine are calcium-blocking agents that have a selective dilator effect on resistance vessels. Both drugs have been shown to lower arterial pressure when given in long-term therapy under conditions of a double-blind controlled trial. Both agents may be effective as sole therapy or when given in combination with a diuretic; nifedipine has been used successfully in conjunction with beta-adrenoceptor antagonist/diuretic combinations. Calcium-blocking agents do not evoke tolerance in long-term treatment; in contrast to other directly acting dilator drugs, they do not consistently lead to a rise in plasma renin activity and they induce little or no sodium retention. Calcium-blocking agents do not all share the same mechanism of action, and they vary considerably in their effect on the heart. These differences may be important in determining which compound is best suited for use in particular clinical situations.
维拉帕米和硝苯地平是钙阻滞剂,对阻力血管有选择性扩张作用。在双盲对照试验条件下进行长期治疗时,这两种药物均已显示能降低动脉血压。这两种药物既可以作为单一疗法有效,也可以与利尿剂联合使用;硝苯地平已成功地与β-肾上腺素能受体拮抗剂/利尿剂联合使用。钙阻滞剂在长期治疗中不会产生耐受性;与其他直接作用的扩张剂药物不同,它们不会持续导致血浆肾素活性升高,并且很少或不会引起钠潴留。钙阻滞剂并非都具有相同的作用机制,它们对心脏的作用差异很大。这些差异在确定哪种化合物最适合用于特定临床情况时可能很重要。